Skip to content
OpenCapital
Get started

Denali Therapeutics Inc. DNLI Milestone Payment — Total collaboration revenue

Other product segments

Milestone Triggered
$25M—
Option Fee Payment
$2.5M+100%

Similar metrics at other companies

Incyte logo
INCYMilestone and contract revenues — Total revenues
$17M—
Dianthus Therapeutics logo
DNTHMilestone — Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
$7M+600%
Axsome Therapeutics logo
AXSMMilestone Revenue — Revenue
$500K—
Exelixis logo
EXELCollaboration services revenues — Revenue from contract with customer, commercial sales milestone
$2.4M—
Cytokinetics logo
CYTKCollaboration Revenues — Revenue
$2.64M+67.0%
Dianthus Therapeutics logo
DNTHMilestone — Revenue Recognition Milestone Method Pending
$15M0.0%

Other financials

Income statement

See full
Revenue-—
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0×0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s milestone payment — total collaboration revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s milestone payment — total collaboration revenue?
Denali Therapeutics Inc. (DNLI) reported milestone payment — total collaboration revenue of $2.5M in Q4 2026.
How has Denali Therapeutics Inc.'s milestone payment — total collaboration revenue changed year-over-year?
Denali Therapeutics Inc.'s milestone payment — total collaboration revenue decreased by 0.0% year-over-year, from $2.5M to $2.5M.
What is the long-term trend for Denali Therapeutics Inc.'s milestone payment — total collaboration revenue?
Over 2 years (2024 to 2026), Denali Therapeutics Inc.'s milestone payment — total collaboration revenue has grown at a 0.0% compound annual growth rate (CAGR), from $10M to $10M.
What does milestone payment — total collaboration revenue mean?
This metric represents the total revenue recognized from milestone payments received through strategic research and development collaborations. These payments are typically triggered by the achievement of specific clinical, regulatory, or commercial objectives within a partnership agreement. It serves as a key indicator of the company's ability to successfully advance its pipeline assets and validate its proprietary technology platforms through external validation.